Clinical trials: Substance Related Disorder
Alcohol Dependence
Effectiveness of Gabapentin When Used With Naltrexone to Treat Alcohol Dependence Compared to Placebo and Naltrexone Alone
The purpose of this study is to determine whether, after a period of abstinence, adding 6 weeks of gabapentin (a medication approved to treat seizures) to a standard 16-week naltrexone (an opiate blocking agent approved for the…
- Trial name
- NCT00183196
- Testing
- Naltrexone, Naltrexone plus Gabapentin
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Medical University of South Carolina
Alcoholism
ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)
This was a Phase 3 multicenter randomized, open-label, safety study assessing the safety of repeat doses of Medisorb® naltrexone 380 mg (VIVITROL®) administered for up to 1 year to adults with alcohol and/or opioid dependence as…
- Trial name
- NCT01218997
- Testing
- Medisorb naltrexone 380 mg, Oral naltrexone 50 mg
- Volunteers
- 436 people
- Sponsor
- Alkermes, Inc.
Opioid-use Disorder
Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment
This is an open-label pilot trial to evaluate the safety and tolerability of lofexidine in the management of opioid withdrawal symptoms while initiating outpatient treatment with naltrexone.
- Trial name
- NCT04056182
- Testing
- Lofexidine 0.18 MG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York State Psychiatric Institute
Bipolar Disorder, Cocaine Dependence
Citicoline for Bipolar 1 Disorder and Cocaine Dependence
A 12-week, randomized, double-blind, parallel-group, placebo-controlled trial of citicoline as an add-on therapy will be conducted in 200 outpatients with bipolar I disorder and cocaine dependence.
- Trial name
- NCT00619723
- Testing
- Citicoline, Cognitive Behavioral Therapy (CBT)
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Alcohol Dependence
Study of Acamprosate to Prevent Alcohol Relapse in Criminal Justice Supervisees
The purpose of this study is to test how tolerable and effective acamprosate is when used to prevent alcohol relapse in criminal justice supervisees (those on probation, parole, or in drug court).
- Trial name
- NCT00249379
- Testing
- Acamprosate
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Virginia Commonwealth University
Nicotine Dependence
Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation
Randomized trial to evaluate whether zonisamide can enhance varenicline-induced smoking cessation.
- Trial name
- 1207 (NCT01685996)
- Testing
- zonisamide
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Johns Hopkins University
Alcoholism, Depression
Naltrexone & SSRI in Alcoholics With Depression/PTSD
The purpose of this study is to evaluate the efficacy of naltrexone in combination with an SSRI to reduce alcohol consumption in alcoholic patients with comorbid PTSD and depression.
- Conditions
- Alcoholism, Depression, PTSD
- Trial name
- NCT00338962
- Testing
- paroxetine, desipramine, Naltrexone
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Yale University
Binge Drinking
An Open Label Trial of Bupropion and Naltrexone for Binge Drinking
This is an open-label Phase IIa pilot study of the tolerability and effects on binge drinking of bupropion and naltrexone for binge drinkers.
- Trial name
- NCT02842073
- Testing
- Naltrexone, Bupropion
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of North Carolina, Chapel Hill
Poor Quality Sleep, Opiate Addiction
Insomnia and Drug Relapse Risk
The purposes of this study are: 1. to evaluate the relationship between subjective complaints of sleep and objective measures of sleep quality, as measured through polysomnography, and 2.
- Trial name
- NCT00253890
- Testing
- Trazodone
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Butler Hospital
Opioid-use Disorder, Recidivism
Fostering MAT Use in Justice Populations
The grant will test two timely and successful evidence-based implementation practices, NIATx Coaching and ECHO, with jail/community-based healthcare providers to increase medication assisted treatment (MAT) use with justice…
- Trial name
- NCT04363320
- Testing
- NIATx Coaching, ECHO
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- University of Wisconsin, Madison
Marijuana Usage, Opioid Use
Opioid and Cannabinoid Interactions
This study will examine the effects of doses of marijuana/placebo and doses of opioid/placebo, alone and in combination. The primary outcomes are related to pharmacodynamic measures (subjective ratings of drug liking and other…
- Trial name
- NCT03705559
- Testing
- Vaporized Marijuana, Opioid Agonist
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Shanna Babalonis, PhD
Cannabis-Related Disorder, Substance-Related Disorders
First Episode Schizophrenia and Cannabis-Related Disorder Study
Many individuals with schizophrenia abuse cannabis at the onset of their illness, portending a poorer course of illness and poorer treatment response.
- Conditions
- Cannabis-Related Disorder, Substance-Related Disorders, Schizophrenia, Psychotic Disorders
- Trial name
- NCT00573287
- Testing
- clozapine, risperidone
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Alcohol Use Disorder
Ibudilast for the Treatment of Alcohol Use Disorder
This study is a double-blind, placebo-controlled randomized clinical trial of Ibudilast (IBUD) (50mg twice a day) for the treatment of Alcohol Use Disorder (AUD).
- Trial name
- NCT03594435
- Testing
- Ibudilast
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of California, Los Angeles
Nicotine Addiction, Smoking Cessation
Evaluation of a Smoking Cessation Program for Long-Term Abstinence
This observational study evaluates a structured smoking cessation program delivered via weekly group sessions. The primary objective is to assess participant-reported smoking abstinence following completion of the program and at…
- Trial name
- ESCaPe (NCT06746025)
- Testing
- Quit Center cessation program
- Where
- United States
- Volunteers
- 371 people
- Sponsor
- Quit Center LLC
Alcohol Drinking, Problem Drinking
Testing Brief Personalized Feedback Integrating EMA Alcohol Cue Information
This study aims to develop a brief intervention that incorporates ecological momentary assessments (EMAs; i.e., four brief surveys per day for 17 days) to create personalized feedback targeting high-risk alcohol use among young…
- Trial name
- Project ACE (NCT05373706)
- Testing
- Alcohol Cue Reactivity Personalized Feedback Intervention
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- University of Washington
Depression, Opioid-use Disorder
Ketamine for the Treatment of Opioid Use Disorder and Depression
The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine…
- Conditions
- Depression, Opioid-use Disorder, Opioid Abuse
- Trial name
- NCT04177706
- Testing
- Ketamine Hydrochloride
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Medical University of South Carolina
Alcohol Use Disorder, Alcohol Dependence
Altering Memories That Increase Risk of Relapse in Alcohol Use Disorders
The purpose of this study is to examine the effects of rapamycin (sirolimus) versus a placebo, an inactive substance, on responses to alcohol cues in individuals with alcohol use disorder.
- Trial name
- NCT03732248
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Alcohol Dependence
Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability.
The purpose of this study is to determine whether naltrexone (an opiate blocking agent approved for the treatment of alcohol dependence) is more effective in the reduction of alcohol craving and drinking compared to placebo in…
- Trial name
- NCT00366626
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Medical University of South Carolina
Alcohol Use Disorder
Increasing the Temporal Window in Individuals With Alcohol Use Disorder
Episodic future thinking (EFT) is based on the new science of prospection, which was first identified in a Science publication in 2007 and refers to pre-experiencing the future by simulation.
- Trial name
- RP1A (NCT04125238)
- Testing
- Episodic Future Thinking, Control Episodic Thinking
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Virginia Polytechnic Institute and State University
Alcohol Use Disorder, Post Traumatic Stress Disorder
Piloting "Signs of Safety": A Deaf-Accessible Therapy Toolkit for Alcohol Use Disorder and Trauma
The U.S. Deaf community - more than 500,000 Americans who communicate using American Sign Language (ASL) - experiences nearly triple the rate of lifetime problem drinking and twice the rate of trauma exposure as compared to the…
- Trial name
- NCT03845985
- Testing
- Seeking Safety + Signs of Safety toolkit
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Massachusetts, Worcester
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.